Crossmark

Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)

Crossref DOI link: https://doi.org/10.1186/s12885-025-15066-z

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hong, Angela M.

Wang, Tim

Carlino, Matteo S.

Lo, Serigne N.

Menzies, Alexander M.

da Silva, Inês Pires

Long, Georgina V.
Funding

Funding for this research was provided by:

Trial funding through the Varian Research Grants Program supplied by Varian USA to GenesisCare Australia
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 2 July 2025

Accepted: 16 September 2025

First Online: 21 October 2025

Declarations

:

: The trial protocol was reviewed and approved by the St Vincent’s Hospital Human Research Ethics Committee on 28th May 2025 (protocol number 2024/ETH02617). Written informed consent will be obtained from all trial participants.

: not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below